- Home
- CHRS vs KLRS Comparison
CHRS vs KLRS Comparison
Compare CHRS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- KLRS
- Stock Information
- Founded
- CHRS 2010
- KLRS 2019
- Country
- CHRS United States
- KLRS United States
- Employees
- CHRS N/A
- KLRS N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRS Health Care
- KLRS Health Care
- Exchange
- CHRS Nasdaq
- KLRS Nasdaq
- Market Cap
- CHRS 112.5M
- KLRS 129.0M
- IPO Year
- CHRS 2014
- KLRS N/A
- Fundamental
- Price
- CHRS $0.76
- KLRS $2.66
- Analyst Decision
- CHRS Buy
- KLRS Buy
- Analyst Count
- CHRS 3
- KLRS 1
- Target Price
- CHRS $4.68
- KLRS N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- KLRS 49.7K
- Earning Date
- CHRS 08-07-2025
- KLRS 05-14-2025
- Dividend Yield
- CHRS N/A
- KLRS N/A
- EPS Growth
- CHRS N/A
- KLRS N/A
- EPS
- CHRS N/A
- KLRS N/A
- Revenue
- CHRS $272,251,000.00
- KLRS N/A
- Revenue This Year
- CHRS N/A
- KLRS N/A
- Revenue Next Year
- CHRS $132.69
- KLRS N/A
- P/E Ratio
- CHRS $1.79
- KLRS N/A
- Revenue Growth
- CHRS 19.87
- KLRS N/A
- 52 Week Low
- CHRS $0.66
- KLRS $2.45
- 52 Week High
- CHRS $2.43
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- KLRS N/A
- Support Level
- CHRS $0.74
- KLRS N/A
- Resistance Level
- CHRS $0.90
- KLRS N/A
- Average True Range (ATR)
- CHRS 0.05
- KLRS 0.00
- MACD
- CHRS 0.01
- KLRS 0.00
- Stochastic Oscillator
- CHRS 13.56
- KLRS 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.